These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 36704723)

  • 21. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer.
    Dong B; Wu Y; Zhang J; Gu Y; Xie R; He X; Pang X; Wang X; Cui Y
    Front Immunol; 2023; 14():1162876. PubMed ID: 37215130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer.
    Gan X; Tang X; Li Z
    Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.
    Yao K; Zhou E; Cheng C
    Cancer Med; 2022 Feb; 11(4):1232-1243. PubMed ID: 35044091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
    Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
    Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
    Guo X; Xu Y; Zhao Z
    Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-cancer analyses of immunogenic cell death-derived gene signatures: Potential biomarkers for prognosis and immunotherapy.
    Han X; Song D; Cui Y; Shi Y; Gu X
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2073. PubMed ID: 38627900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of immunogenic cell death-related subtypes used for predicting survival and immunotherapy of endometrial carcinoma through a bioinformatics analysis.
    Liu Z; Luo Y; Su L; Hu X
    Medicine (Baltimore); 2023 Aug; 102(31):e34571. PubMed ID: 37543760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Necroptosis-Related Gene Signature to Predict the Prognosis of Skin Cutaneous Melanoma.
    Xie Y; Xu Z; Mei X; Shi W
    Dis Markers; 2022; 2022():8232024. PubMed ID: 36438905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma.
    Scatolini M; Patel A; Grosso E; Mello-Grand M; Ostano P; Coppo R; Vitiello M; Venesio T; Zaccagna A; Pisacane A; Sarotto I; Taverna D; Poliseno L; Bergamaschi D; Chiorino G
    Br J Dermatol; 2022 Jan; 186(1):117-128. PubMed ID: 34240406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
    Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma.
    Zhou X; Xu R; Lu T; Wang C; Chang X; Peng B; Shen Z; Yao L; Wang K; Xu C; Shi J; Zhang R; Zhao J; Zhang L
    Sci Rep; 2023 Aug; 13(1):13305. PubMed ID: 37587188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
    Sevilla A; Morales MC; Ezkurra PA; Rasero J; Velasco V; Cancho-Galan G; Sánchez-Diez A; Mujika K; Penas C; Smith I; Asumendi A; Cortés JM; Boyano MD; Alonso S
    PLoS One; 2020; 15(3):e0230136. PubMed ID: 32168325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.